Chemical Structure of Capivasertib: A Novel AKT Inhibitor

Capivasertib is a novel oral targeted anticancer drug classified as an AKT inhibitor. It exerts antitumor effects by interfering with the PI3K/AKT signaling pathway, thereby disrupting signals driving abnormal tumor cell proliferation. Understanding its chemical structure provides insight into its development and mechanism of action.

1. Basic Chemical Structure Information​

The chemical name of capivasertib is Capivasertib, with a molecular formula of C₂₁H₂₅ClN₆O₂ and a molecular weight of approximately 428.9. As a small-molecule compound, it binds specifically to AKT protein through its unique chemical configuration, inhibiting AKT signaling activity. Unlike conventional chemotherapy, small-molecule targeted drugs have defined targets, and their molecular design focuses on improving binding affinity, stability, and in vivo efficacy.

2. Relationship Between Chemical Structure and Mechanism​

The molecular structure of capivasertib enables selective binding to AKT, disrupting signal transduction along the AKT pathway. AKT is a crucial intracellular signaling regulator involved in tumor cell survival, growth, and drug resistance. In some breast cancer patients, PIK3CA mutations, AKT1 hyperactivation, or PTEN loss lead to constitutive AKT pathway activation, fueling tumor progression. Capivasertib precisely blocks this pathway to inhibit tumor growth.

3. Drug Classification: AKT Pathway Inhibitor​

By classification, capivasertib is an AKT pathway inhibitor, a key category in precision oncology. Its development focuses on intervening in specific aberrant signals within cancer cells rather than broadly affecting all rapidly dividing cells as traditional chemotherapy does, thereby reducing off-target toxicity.

4. Significance of Chemical Structure Research​

A drug’s chemical structure determines how it binds to its target and influences absorption, distribution, and metabolism. Through structural optimization, capivasertib achieves more precise targeting of AKT, offering a new therapeutic tool for breast cancer and related malignancies.